ACT1VATE: Addressing Emotional Distress to Improve Outcomes Among Diverse Adults With Type 1 Diabetes

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorScripps Whittier Diabetes Institute

About this trial

This research will compare a psychological intervention ("ACT1VATE") versus diabetes self-management education and support (DSME/S; usual care) in improving clinical, behavioral, psychosocial, process, and cost outcomes among adults with poorly controlled type 1 diabetes (T1D) who are experiencing significant diabetes-related emotional distress and poor glycemic control in a real world, healthcare environment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Spanish or English-speaking

Type 1 diabetes

Glycosylated Hemoglobin (HbA1c) 7.0% - 12.5% in last 90 days

Screen positive for diabetes distress

Disqualifiers

Severe medical or psychological conditions that would interfere with participation based on the opinion of a provider

Plans to move out of the San Diego area in the next 12 months

Lack of technology capability required to complete online surveys and telemedicine visit

Trial design

Design model

Parallel

Treatments tested in this trial

  • ACT1VATE

    Behavioral

    ACT1VATE, informed by Acceptance and Commitment Therapy (ACT), will consist of five, 90-minute group-based telemedicine therapy sessions delivered by a Behavioral Health Provider.

  • DSME/S

    Behavioral

    Diabetes self-management education and support (DSME/S) will be delivered by a Certified Diabetes Care and Education Specialist via one-on-one telemedicine format.

Treatment groups

250 Participants
are divided into 2 treatment groups
Group A: ACT1VATEExperimental treatment 1 intervention
Group B: DSME/S (usual care)Active comparator 1 intervention

Trial outcomes

Primary outcomes

1

Glycosylated Hemoglobin (HbA1c)

HbA1c (%) reflects average glucose over the past 2-3 months, with higher values indicating greater risk for developing diabetes-related complications. HbA1c for up to 5 data points (0, 3, 6, 9, 12 months) will be analyzed. Multilevel models using full information maximum likelihood estimation will be conducted to examine HbA1c changes. Analyses will include the between-subjects factor of group and the within-subjects factor of time. Month 0 will be the referent time-point with post-intervention and follow-up time-points as comparison time-points in dummy-coded predictors. The group by time interaction is of primary interest. If an interaction is found significant, follow-up analyses will determine the nature of differential change between treatment conditions.

Time frame
Baseline, 3 months, 6 months, 9 months, 12 months
2

Diabetes Distress Scale

The Type 1 Diabetes Distress Scale (T1-DDS; 28 items averaged to obtain a total score ranging 1-6, with higher scores indicating greater diabetes-related emotional stress) will be analyzed. Multilevel models using full information maximum likelihood estimation will be conducted to examine change in diabetes distress over time. Analyses will include the between-subjects factor of group and the within-subjects factor of time. Month 0 will be the referent time-point with post-intervention and follow-up time-points as comparison time-points in dummy-coded predictors. The group by time interaction is of primary interest. If an interaction is found significant, follow-up analyses will determine the nature of differential change between treatment conditions.

Time frame
Baseline, 6 months, 12 months

Secondary outcomes

1

Summary of Diabetes Self-Care Activities Survey

Seven items regarding dietary and exercise behaviors from the Summary of Diabetes Self-Care Activities scale (SDSCA; items averaged to obtain a total score for each behavioral domain, ranging from 0-7, with higher scores indicating better outcomes/greater adherence to diabetes self-management behaviors) will be analyzed. Multilevel models using full information maximum likelihood estimation will be conducted to examine behavioral changes. Analyses will include the between-subjects factor of group and the within-subjects factor of time. Month 0 will be the referent time-point with post-intervention and follow-up time-points as comparison time-points in dummy-coded predictors. The group by time interaction is of primary interest. If an interaction is found significant, follow-up analyses will determine the nature of differential change between treatment conditions.

Time frame
Baseline, 6 months, 12 months
2

Generalized Anxiety Disorder Assessment

The Generalized Anxiety Disorder Assessment (GAD-7; 7 items are summed to obtain a total score, ranging from 0 to 21, with higher scores indicating worse outcomes/greater anxiety symptoms) will be analyzed. Multilevel models using full information maximum likelihood estimation will be conducted to examine anxiety symptom changes over time. Analyses will include the between-subjects factor of group and the within-subjects factor of time. Month 0 will be the referent time-point with post-intervention and follow-up time-points as comparison time-points in dummy-coded predictors. The group by time interaction is of primary interest. If an interaction is found significant, follow-up analyses will determine the nature of differential change between treatment conditions.

Time frame
Baseline, 6 months, 12 months
3

Patient Health Questionnaire-8

Patient Health Questionnaire (PHQ-8; 8 items averaged to obtain a total score, with higher scores indicating worse outcomes/greater depressive symptomatology) will be analyzed. Multilevel models using full information maximum likelihood estimation will be conducted to examine depressive symptom changes over time. Analyses will include the between-subjects factor of group and the within-subjects factor of time. Month 0 will be the referent time-point with post-intervention and follow-up time-points as comparison time-points in dummy-coded predictors. The group by time interaction is of primary interest. If an interaction is found significant, follow-up analyses will determine the nature of differential change between treatment conditions.

Time frame
Baseline, 6 months, 12 months
4

Perceived Stress Scale

Perceived Stress Scale (PSS-4; 4 items are summed to obtain a total score, ranging from 0-16, higher scores indicating worse outcomes/greater levels of perceived stress) will be analyzed. Multilevel models using full information maximum likelihood estimation will be conducted to examine stress level changes over time. Analyses will include the between-subjects factor of group and the within-subjects factor of time. Month 0 will be the referent time-point with post-intervention and follow-up time-points as comparison time-points in dummy-coded predictors. The group by time interaction is of primary interest. If an interaction is found significant, follow-up analyses will determine the nature of differential change between treatment conditions.

Time frame
Baseline, 6 months, 12 months

Other outcomes

1

Cost-effectiveness

Long-term cost-effectiveness of ACT1VATE will use a simulation model. The UKPDS Outcomes Model Risk Engine (UKPDS-OM) developed the predictive equations for diabetes-related complications, mortality, and assigned utilities conditional on disease. Estimated clinical effects + costs of each arm will be inputs into the UKPDS-OM model. Estimated clinical effects (HbA1c change) come from Aim 1. Intervention costs will be estimated using standard accounting methods, process mapping + time-based activity costing. Base case assumes a health system perspective, 40-year time horizon, and 3% discount rate for both QALY and costs. Sensitivity analyses will investigate the influence of the estimated treatment effects and intervention costs, the influence of time horizon and discount rate, and second order uncertainty. UKPDS-OM provides equation parameters derived from bootstrap samples of the original UKPDS population. Estimates will be used to calculate an incremental cost-effectiveness plan.

Time frame
12 months
2

Diabetes-Specific Self Compassion Scale

Diabetes-Specific Self-Compassion Scale (D-SCS; range 0-5 with higher scores indicating higher levels of diabetes-specific self-compassion) will be analyzed to evaluate theoretical fidelity. Multilevel models using full information maximum likelihood estimation will be conducted to examine change in the construct over time. Analyses will include the between-subjects factor of group and the within-subjects factor of time. Month 0 will be the referent time-point with post-intervention and follow-up time-points as comparison time-points in dummy-coded predictors. The group by time interaction is of primary interest. If an interaction is found significant, follow-up analyses will determine the nature of differential change between treatment conditions.

Time frame
Baseline, 6 months, 12 months
3

Acceptance and Action Diabetes Questionnaire

The Acceptance and Action Diabetes Questionnaire (AADQ; a 6-item scale measuring cognitive avoidance related to diabetes with higher scores indicating higher levels of cognitive avoidance) will be analyzed to evaluate theoretical fidelity. Multilevel models using full information maximum likelihood estimation will be conducted to examine change in the construct over time. Analyses will include the between-subjects factor of group and the within-subjects factor of time. Month 0 will be the referent time-point with post-intervention and follow-up time-points as comparison time-points in dummy-coded predictors. The group by time interaction is of primary interest. If an interaction is found significant, follow-up analyses will determine the nature of differential change between treatment conditions.

Time frame
Baseline, 6 months, 12 months
4

Body Mass Index (BMI)

Body Mass Index (BMI) - will be measured as Weight in kg/Height squared in meters. BMI for up to 5 data points (0, 3, 6, 9, 12 months) will be analyzed. Multilevel models using full information maximum likelihood estimation will be conducted to examine BMI changes. Analyses will include the between-subjects factor of group and the within-subjects factor of time. Month 0 will be the referent time-point with post-intervention and follow-up time-points as comparison time-points in dummy-coded predictors. The group by time interaction is of primary interest. If an interaction is found significant, follow-up analyses will determine the nature of differential change between treatment conditions.

Time frame
Baseline, 3 months, 6 months, 9 months, 12 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Scripps Whittier Diabetes Institute

Lead sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator